Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices

Transfusion - Tập 54 Số 5 - Trang 1418-1437 - 2014
Ratti Ram Sharma1, Kathryn Pollock2, Allison Hubel3, David H. McKenna4
1Department of Transfusion Medicine Post graduate Institute of Medical Education and Research Chandīgarh India
2Department of Biomedical Engineering University of Minnesota Saint Paul Minnesota
3Department of Mechanical Engineering, University of Minnesota, Saint Paul, Minnesota
4Department of Laboratory Medicine and Pathology; University of Minnesota; Saint Paul Minnesota

Tóm tắt

Mesenchymal stem cells (MSCs) have recently generated great interest in the fields of regenerative medicine and immunotherapy due to their unique biologic properties. In this review we attempt to provide an overview of the current clinical status of MSC therapy, primarily focusing on immunomodulatory and regenerative or tissue repair applications of MSCs. In addition, current manufacturing is reviewed with attention to variation in practices (e.g., starting material, approach to culture and product testing). There is considerable variation among the 218 clinical trials assessed here; variations include proposed mechanisms of action, optimal dosing strategy, and route of administration. To ensure the greatest likelihood of success in clinical trials as the field progresses, attention must be given to the optimization of MSC culture.

Từ khóa


Tài liệu tham khảo

10.1097/00007890-196803000-00009

10.1091/mbc.e02-02-0105

10.1634/stemcells.2004-0058

10.1016/j.exphem.2005.07.003

10.1634/stemcells.2005-0342

10.1016/j.cellbi.2007.12.007

10.1080/14653240600855905

10.3324/haematol.13699

10.1186/1756-8722-5-19

10.1186/1755-1536-4-20

Lazarus HM, 1995, Ex vivo expansion and subsequent infusion of human bone marrow‐derived stromal progenitor cells: implications for therapeutic use, Bone Marrow Transplant, 16, 557

10.1038/81395

10.1016/j.trim.2008.08.004

10.1097/01.TP.0000045055.63901.A9

10.1634/stemcells.2004-0359

10.1097/01.tp.0000267918.07906.08

10.3324/haematol.11446

10.1182/blood.V99.10.3838

10.1089/154732804323099190

10.1182/blood-2008-04-154138

10.1182/blood-2005-07-2657

10.1016/j.exphem.2009.01.005

10.1182/blood-2005-07-2775

10.1182/blood-2004-04-1559

10.1111/j.1365-2249.2009.03874.x

10.1378/chest.10-0518

10.1182/blood-2002-06-1830

10.1634/stemcells.2007-0637

10.1016/S0140-6736(04)16104-7

10.1016/S0140-6736(08)60690-X

10.3324/haematol.2010.038356

10.1007/s12185-011-0989-2

10.1016/j.bbmt.2010.04.014

10.3109/14653240903390795

Zhang LS, 2009, [Mesenchymal stem cells for treatment of steroid‐resistant chronic graft‐versus‐host disease], Zonghua Nei Ke Za Zhi, 48, 542

10.1016/j.bbmt.2009.11.006

10.1016/j.bbmt.2008.03.012

10.1097/01.tp.0000214462.63943.14

Hou RQ, 2010, Transfusion of mesenchymal stem cells combined with haploidentical HSCT improves hematopoietic microenvironment, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 18, 155

10.1016/j.bbmt.2010.01.011

10.1111/j.1751-553X.2009.01181.x

Wu T, 2009, Autologous bone marrow‐derived mesenchymal stem cells and peripheral blood stem cells cotransplantation in treatment of hematological malignant diseases, Zhonghua Nei Ke Za Zhi, 48, 392

10.1038/sj.leu.2405090

10.1038/bmt.2008.348

10.1016/j.bcmd.2007.06.021

10.1182/blood-2007-04-087056

10.1016/j.bbmt.2005.02.001

10.1200/JCO.2000.18.2.307

10.1089/scd.2009.0029

10.1089/scd.2010.0447

10.1056/NEJMoa1207285

10.1136/ard.2009.123463

10.1002/stem.68

10.1001/jama.2012.316

10.2215/CJN.04950610

10.1016/j.jneuroim.2010.07.013

Mohyeddin Bonab M, 2007, Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study, Iran J Immunol, 4, 50

10.1002/ana.23612

10.1038/sj.clpt.6100386

10.1016/S1474-4422(11)70305-2

10.1002/jor.1100090504

10.1111/j.1600-0609.2005.00611.x

10.1038/sj.bmt.1705798

10.1073/pnas.1432929100

10.1038/gt.2008.39

10.3727/096368910X508762

10.1038/nature00870

10.1182/blood-2003-05-1670

10.1007/s11517-007-0163-4

10.1038/nm.3028

10.1016/S0014-4827(03)00132-0

10.1161/01.CIR.0000084828.50310.6A

10.1634/stemcells.2008-0428

10.1002/bdrc.20174

10.1016/j.molmed.2010.02.005

10.1359/jbmr.1999.14.5.700

10.1111/j.1582-4934.2007.00205.x

10.1186/1471-2121-11-29

10.1002/hep.22236

10.1186/1479-5876-10-66

10.1016/j.jacc.2009.06.055

10.1111/j.1755-5922.2009.00116.x

Chen SL, 2004, Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction, Chin Med J (Engl), 117, 1443

Mohyeddin‐Bonab M, 2007, Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction, Arch Iran Med, 10, 467

10.1002/ccd.20406

10.3109/14017431.2011.569571

10.1161/CIRCRESAHA.111.242610

10.1177/0218492309349363

Chen S, 2006, Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery, J Invasive Cardiol, 18, 552

Wang JA, 2006, A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy, Zhonghua Xin Xue Guan Bing Za Zhi, 34, 107

10.1111/j.1440-1746.2011.07024.x

10.1097/MEG.0b013e3283488b00

10.1097/MEG.0b013e32832a1f6c

Mohamadnejad M, 2007, Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis, Arch Iran Med, 10, 459

10.1016/j.diabres.2010.12.010

10.1177/0003319710364213

10.1089/rej.2009.0872

10.1089/ten.2006.0278

10.1093/brain/awr063

10.1002/stem.430

10.1002/ana.20501

10.3109/14653240903253857

10.1111/j.1756-185X.2011.01599.x

Chang T, 2010, Treatment of early avascular necrosis of femoral head by core decompression combined with autologous bone marrow mesenchymal stem cells transplantation, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 24, 739

10.1002/term.299

10.1016/j.biomaterials.2008.03.012

10.1038/sj.bmt.1703650

10.1111/j.1537-2995.2007.01219.x

10.1046/j.1365-2141.2003.04284.x

10.1016/j.brainres.2006.09.044

10.1016/j.trsl.2009.07.006

Centeno CJ, 2008, Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells, Pain Physician, 11, 343

10.1046/j.1365-3083.2003.01176.x

Pamphilon DH, 2009, Practical transfusion medicine, 409

10.1002/9780470259832.ch4

10.1089/hum.2010.197

10.1634/stemcells.22-5-675

10.1016/j.mad.2007.12.002

10.1136/jcp.54.9.657

10.1634/stemcells.2006-0015

10.1080/14653240701218516

10.1016/j.exphem.2008.03.004

10.1002/jcp.21200

Lu LL, 2006, Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis‐supportive function and other potentials, Haematologica, 91, 1017

10.1002/path.2469

10.1634/stemcells.2006-0589

10.1097/01.prs.0000234609.74811.2e

10.1161/01.RES.0000265074.83288.09

10.1080/14653240600621125

10.1007/978-1-60327-169-1_5

10.1089/107632701300062859

10.1097/00006534-200102000-00047

Duckers HJ, 2006, The Bedside Celution™ system for isolation of adipose derived regenerative cells, EuroIntervention, 2, 395

10.1016/j.jvs.2007.02.046

10.1634/stemcells.22-4-625

10.1634/stemcells.2004-0013

10.1634/stemcells.20-6-530

10.1089/ten.2005.0513

10.1634/stemcells.2004-0331

10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I

10.1385/MB:20:3:245

Asher DM, 1999, Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies, Dev Biol Stand, 99, 41

European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products.Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products. EMEA CPMP/BWP/1793/02;2003.

European Agency for the Evaluation of Medicinal Products.Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. EMEA/410/01 rev3;2011.

10.1016/j.ymthe.2004.02.012

10.1073/pnas.132252399

10.1634/stemcells.2007-0127

10.1034/j.1600-0501.2002.130513.x

10.1111/j.1600-0501.2005.01203.x

10.1016/S0142-9612(03)00114-5

Kilian O, 2004, Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro, Eur J Med Res, 9, 337

10.1016/S1079-2104(98)90029-4

10.1097/01.blo.0000165736.87628.12

10.1002/stem.139

10.1634/stemcells.2006-0627

10.1046/j.1537-2995.2002.00149.x

10.1089/107632702320934047

10.1097/01.tp.0000285088.44901.ea

10.1634/stemcells.2005-0094

10.1634/stemcells.2005-0612

10.1126/science.1107627

10.1182/blood-2007-07-103697

10.1006/bbrc.2001.5777

10.1016/j.exphem.2006.07.011

10.1089/107632704323061753

10.1634/stemcells.2005-0117

10.1089/rej.2006.9.31

10.1016/j.bbrc.2007.08.161

10.1073/pnas.141221698

10.1016/S0301-472X(00)00160-0

10.3109/14653249.2010.507330

10.1089/ten.tec.2008.0060

Sensebé L, 2008, Clinical grade production of mesenchymal stem cells, Biomed Mater Eng, 18, S3

10.1634/stemcells.2005-0591

10.3727/000000007783465172

Rojewski M, 2010, A standardized protocol for GMP compliant expansion of MSC from BM in an animal component free system, Vox Sang, 99, 43

10.1002/jcp.20571

10.3390/ijms14012119

McGuiganD.Current news releases. Source: December 21; Stemedica Cell Technologies Inc. Dec 12 2012. [cited 2012 Dec 27]. Available from:http://www.stemedica.com.

10.4161/org.5.3.9585

Munson TE, 1985, Guideline for validation of the LAL test as an end‐product endotoxin test for human and biological products, Prog Clin Biol Res, 189, 211

10.1159/000128968

10.1007/s12272-009-1125-1

10.1371/journal.pone.0002213

10.1182/blood-2009-05-219907

Friedenstein AJ, 1974, Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method, Exp Hematol, 2, 83

10.1089/ten.tec.2008.0060

Thông tin
Thông tin xuất bản

Transfusion

Tập 54 Số 5

1418-1437

Thông tin tác giả